Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Assets (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Other Non-Current Assets for 6 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 20.27% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 20.27% decrease, with the full-year FY2024 number at $5.5 million, up 248.11% from a year prior.
  • Other Non-Current Assets was $3.8 million for Q3 2025 at Caribou Biosciences, up from $3.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.5 million in Q4 2024 to a low of $810000.0 in Q3 2021.
  • A 5-year average of $2.4 million and a median of $1.6 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 61.63% in 2022, then skyrocketed 248.11% in 2024.
  • Caribou Biosciences' Other Non-Current Assets stood at $975000.0 in 2021, then skyrocketed by 57.74% to $1.5 million in 2022, then increased by 3.12% to $1.6 million in 2023, then surged by 248.11% to $5.5 million in 2024, then plummeted by 31.53% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Other Non-Current Assets are $3.8 million (Q3 2025), $3.6 million (Q2 2025), and $5.0 million (Q1 2025).